medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2015; 67 (2)


Hepatitis C Screening in the General Population

Corona-Lau C, Muñoz L, Wolpert E, Aguilar LM, Dehesa M, Gutiérrez C, Kershenobich D

Idioma: Ingles.
Referencias bibliográficas: 38
Paginas: 104-108
Archivo PDF: 176.49 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Center for Disease Control and Prevention. MMWR Recomm Rep. 2003; 52:1-13.

  2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335-74.

  3. Gullett JC, Nolte FS. Quantitative nucleic acid amplification methods for viral infections. Clin Chem. 2015;61:72-8.

  4. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.

  5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331-8.

  6. Ward JW. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013;21:15-9.

  7. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45-57.

  8. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm J Viral Hepat. 2014;21(Suppl 1):34-59.

  9. Gane E, Kershenobich D, Seguin-Devaux C, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden J Viral Hepat. 2015;22(Suppl 1):46-73.

  10. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945- 1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:817-22.

  11. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011;31:18-29.

  12. Selvarajah S, Busch MP. Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther. 2012;17: 1423-9.

  13. Alter HJ, Houghton M. Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med. 2000;6:1082-6.

  14. Arain A, Robaeys G, Stöver H. Hepatitis C in European prisons: a call for an evidence-informed response. BMC Infect Dis. 2014; 14(Suppl 6):S17.

  15. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health. 2014;104:816-21.

  16. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014;21:616-23.

  17. Lee M-H, Yang H-I, Yuan Y, L’Italien G, Chen C-J. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014;20:9270-80.

  18. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 2011;31(Suppl 2):30-60.

  19. Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther. 2011;33:559-65.

  20. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-31.

  21. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61:783-9.

  22. Kupek E1, Petry A. Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening. Rev Soc Bras Med Trop. 2014;47:418-25.

  23. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot- Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608.

  24. Linas BP, Hu H, Barter DM, Horberg M, Hepatitis C screening trends in a large integrated health system. Am J Med. 2014;127: 398-405.

  25. Talaat N, Yapali S, Fontana RJ, Conjeevaram HS, Lok AS. Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. J Viral Hepat. 2015; 22:481-8.

  26. Oliveira AC, Bortotti AC, Nunes NN, El Bacha IA, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz J Infect Dis. 2014;18:507-11.

  27. Wang L, Xing J, Chen F, et al. Spatial analysis on hepatitis C virus infection in Mainland China: From 2005 to 2011. PLoS One. 2014;9:e110861.

  28. Schanzer DL, Paquette D, Lix LM. Historical trends and projected hospital admissions for chronic hepatitis C infection in Canada: a birth cohort analysis. CMAJ Open. 2014;2:E139-44.

  29. Oliveira AC, Bortotti AC, Nunes NN, El Bacha IA, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz J Infect Dis. 2014;18:507-11.

  30. Valdespino JL, Conde-Gonzalez CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepulveda J. Seroprevalence of hepatitis C in adults in Mexico: an emerging public health problem? Salud Pública Mex. 2007;49(Suppl 3):S395-403.

  31. Cruz-Ruiz MA, López-Díaz F, González-Ibarra FP, Lara-Ortega C, Muñoz-Ledo Guzman AL, Patiño-Lopez GA. Prevalence of antibodies for the hepatitis C virus in the low land (bajio) region of Mexico. Arch Med Res. 2013;44:390-3.

  32. Campollo O, Roman S, Panduro A, et al. Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug Alcohol Depend. 2012;123:269-72.

  33. Romero-Figueroa S, Ceballos-Salgado E, Santillan-Arreygue L, et al. Risk factors associated with hepatitis C virus infection in an urban population of the state of Mexico. Arch Virol. 2012;157: 329-32.

  34. López-Colombo A, Meléndez-Mena D, Sedeño-Monge V, et al. Hepatitis C virus infection in patients and family members attending two primary care clinics in Puebla, Mexico. Ann Hepatol. 2014;13:746-52.

  35. Medina-Mora ME, Borges G, Fleiz C, et al. Prevalence and correlates of drug use disorders in Mexico. Rev Panam Salud Publica. 2006;19:265-76.

  36. Del Pino N, Oubiña JR, Rodríguez-Frías F, et al. Molecular epidemiology and putative origin of hepatitis C virus in random volunteers from Argentina. World J Gastroenterol. 2013;19:5813-27.

  37. Bruggmann P, Berg T, Øvrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;(Suppl 1):5-33.

  38. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60:691-8.




2020     |     www.medigraphic.com